Floatz logo

PEGASPARGASE

Precursor T-Cell Lymphoblastic Leukemia

Therapeutic Advances in Childhood Leukemia Consortiumprotein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Precursor T-Cell Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Sanofi
Phase 2B
Venetoclax
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 2CCC
RANITIDINE
Sanofi
Phase 2CCC
Omacetaxine
First Affiliated Hospital of Zhejiang University
Phase 2CCC

View all 19 →

Same molecule, other indications

PEGASPARGASE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
80 / 100
View asset →
Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →